Clinical Trials
8 trialsNCT07582172 2026-05-12
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT05139004 2025-07-08
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Active not recruiting
NCT00629798 2021-09-24
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00593554 2018-04-10
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Indiana University
Phase 2 Terminated
NCT00460421 2014-12-05
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
Swedish Orphan Biovitrum
Phase 1 Completed
NCT01233921 2014-04-02
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Phase NA Completed
NCT00004061 2013-06-26
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004132 2013-06-26
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
National Cancer Institute (NCI)
Phase 2 Completed